Kalytera Announces Initiation of Phase 2 Clinical Study in Prevention of Graft Versus Host Disease and Agreement with The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team
Initiation of Phase 2 Clinical Study in Prevention of Graft Versus Host Disease
The Phase 2 study is designed to assess the pharmacokinetic and safety profile of multiple doses of CBD for the prevention of GVHD. The study is expected to enroll 36 patients following allogeneic hematopoietic cell transplantation, and will take place at Beilinson Hospital, and one other major medical center in Israel. Results of the study are expected by Q3 2018.
The Company anticipates that, following completion of the Phase 2 study, it will initiate the Phase 3 study as quickly as possible.
“We are focused on advancing this program from its current Phase 2 status to Phase 3 status as quickly and efficiently as possible, and the initiation of this Phase 2 study is an important and essential step in that process,” said Robert Farrell, President and CEO of Kalytera.
The Principal Investigator of the study is Daniel Couriel, M.D., M.S., Director of the Bone Marrow Transplant Program at the University of Utah Health Sciences, School of Medicine.
Other experts in the field of GVHD who will advise the Company with regard to the study include Edmund Waller, M.D., PhD., Professor, Hematology and Medical Oncology, Medicine, and Pathology at Emory University School of Medicine, and Director, Division of Stem Cell Transplantation and Immunotherapy at Winship Cancer Institute of Emory University; and Rafael Duarte, M.D., Ph.D., Director of the Haematopoietic Transplant Programme at the Catalan Oncology Institute in Barcelona.
Agreement with The Salzman Group
Kalytera also announced today that it has entered into an agreement with The Salzman Group (the “Agreement”), under which The Salzman Group will provide clinical study management services in relation to the Phase 2 study, including chemistry, manufacturing and controls (“CMC”) analytics, as well as stability studies, toxicology studies and drug-drug interaction studies, all of which will be required by the FDA to be completed prior to initiation of a Phase 3 pivotal study. The estimated cost of these services is expected to be approximately $1,240,000 over an 11-month period, and Salzman Group has agreed that it will accept payment in common shares of Kalytera for these services, subject to TSX Venture Exchange approval.
“We are pleased to establish this important funding and clinical studies management agreement with The Salzman Group,” said Robert Farrell, President and CEO of Kalytera. “The Salzman Group is an international pharmaceutical development firm with a strong track record and over two decades of comprehensive experience in drug development, including drug design, process scale-up, formulation, efficacy modeling and design and management of clinical studies. This agreement with The Salzman Group will enable Kalytera to advance our Phase 2 program in the prevention of GVHD, and position us to begin Phase 3 clinical testing during the second-half of next year.”
The Salzman Group will invoice Kalytera for this work in fixed amounts, on a monthly basis as specified in the Agreement, and Kalytera will have the option to make payments in either cash or common shares of the Company (“Common Shares”), in accordance with applicable securities laws and TSX Venture Exchange policies. If Kalytera chooses to pay any such invoice through the issuance of Common Shares, the number of shares of Common Shares that will be issued will be based on a ten percent (10%) discount from the closing price of Kalytera’s Common Shares on the TSX Venture Exchange on the trading day prior to the day that Kalytera gives notice to the Salzman Group that it intends to pay the invoice in Common Shares. The Salzman Group will establish an irrevocable selling agreement with its broker to sell such shares on each of the three trading days following deposit of such shares in its brokerage account.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).